News Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Market Closed - Hong Kong S.E. Other stock markets 04:08:16 2024-04-24 am EDT			5-day change	1st Jan Change
17.22 ^HKD	+2.50%		+2.38%	-36.92%

Apr. 09	Ascentage Pharma Chairman Boosts Stake in Firm	MT
Apr. 04	Ascentage Pharma Group Directors Acquire Company Shares	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ascentage Pharma Chairman Boosts Stake in Firm	Apr. 09	MT
Ascentage Pharma Group Directors Acquire Company Shares	Apr. 03	MT
Ascentage Pharma Widens Loss by Nearly 5% in 2023	Mar. 28	MT
Ascentage Pharma Announces 2023 Annual Results	Mar. 28	AQ
Ascentage Pharma Group International Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Ascentage Pharma to Present Preclinical Results of Three Anti-Tumor Drugs at US Cancer Meet	Mar. 05	MT
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting	Mar. 05	CI
Ascentage Pharma's Phase 3 Trial for Chronic Myeloid Leukemia Treatment Gets US FDA Nod; Shares Rise 3%	Feb. 14	MT
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA	Feb. 13	PR
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia	Feb. 13	CI
Ascentage Pharma Trustee Buys 100,000 Shares	Feb. 05	MT
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia Management from the National Comprehensive Cancer Network	Jan. 16	CI
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference	Jan. 01	PR
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib	Dec. 14	CI
Live from ASH 2023, Ascentage Pharma Releases the First Dataset of Bcl-2 Inhibitor Lisaftoclax in Patients with R/R MM, Demonstrating Encouraging ORR and VGPR	Dec. 12	AQ
Live from ASH 2023, Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib	Dec. 12	AQ
Live from ASH 2023, Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%	Dec. 12	AQ
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR	Dec. 10	CI
Small Lymphocytic Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 \| Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, and others.	Dec. 05	AQ
Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication	Nov. 24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Summary

Filters